Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Varlilumab||CDX-1127|CDX127||Varlilumab (CDX-1127) is an activating monoclonal antibody that binds to CD27 and potentially increases antibody-dependent cellular cytotoxicity towards CD27 positive tumor cells (PMID: 22589397, PMID: 32380537).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Hodgkin's lymphoma||not applicable||Varlilumab||Phase I||Actionable||In a Phase I trial, Varlilumab (CDX-1127) was well tolerated in heavily pretreated Hodgkin's lymphoma patients (n=11), and resulted in one patient with stable disease and one patient who achieved a complete response and remained in remission over 33 months following onset of treatment (PMID: 32380537; NCT01460134).||32380537|
|Unknown unknown||follicular lymphoma||not applicable||Varlilumab||Case Reports/Case Series||Actionable||In a Phase I trial, Varlilumab (CDX-1127) was well tolerated in heavily pretreated patients with follicular lymphoma, and resulted in stable disease in three patients (3/5), with disease control lasting between 4.5 and 14 months, including one patient who experienced 5.6 months of stable disease and a 36% reduction of measurable disease (PMID: 32380537; NCT01460134).||32380537|
|Unknown unknown||non-Hodgkin lymphoma||not applicable||Varlilumab||Phase I||Actionable||In a Phase I trial, Varlilumab (CDX-1127) was well tolerated in heavily pretreated patients with B-cell or T-cell non-Hodgkin lymphoma, and resulted in three B-cell patients (3/18, all follicular lymphomas) with stable disease and one T-cell patient (1/5) with stable disease (PMID: 32380537; NCT01460134).||32380537|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02924038||Phase I||IMA950 + Poly ICLC Varlilumab||A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)||Recruiting|
|NCT02284971||Phase I||Varlilumab||Pilot Study of SBRT and CDX-1127 in Prostate Cancer (Prostate-04)||Terminated|
|NCT02270372||Phase I||Varlilumab ONT-10||Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer||Completed|